The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole

The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole

Summary Background Higher body mass index (BMI) is a recognised risk factor for gastro‐oesophageal reflux disease (GERD). Data regarding the impact of BMI on proton pump inhibitor (PPI) therapy are conflicting. Aim To assess the impact of BMI on baseline heartburn symptom severity and frequency and...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Alimentary pharmacology & therapeutics 2013-04, Vol.37 (8), p.810-818
Hauptverfasser: Peura, D. A., Pilmer, B., Hunt, B., Mody, R., Perez, M. C.
Format: Artikel
Sprache:eng
Schlagworte:
2-Pyridinylmethylsulfinylbenzimidazoles - therapeutic use
Adolescent
Adult
Aged
Aged, 80 and over
Biological and medical sciences
Body Mass Index
Clinical Trials as Topic
Dexlansoprazole
Digestive system
Dose-Response Relationship, Drug
Esophagitis - drug therapy
Esophagitis - physiopathology
Female
Gastroenterology. Liver. Pancreas. Abdomen
Gastroesophageal Reflux - drug therapy
Gastroesophageal Reflux - physiopathology
Heartburn
Heartburn - drug therapy
Heartburn - physiopathology
Humans
Lansoprazole
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Proton Pump Inhibitors - therapeutic use
Risk Factors
Severity of Illness Index
Treatment Outcome
Young Adult
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Summary Background Higher body mass index (BMI) is a recognised risk factor for gastro‐oesophageal reflux disease (GERD). Data regarding the impact of BMI on proton pump inhibitor (PPI) therapy are conflicting. Aim To assess the impact of BMI on baseline heartburn symptom severity and frequency and response to PPI therapy in patients with non‐erosive GERD (NERD) or erosive oesophagitis (EO). Methods In post hoc analyses of phase 3 trial data, 621 NERD and 2692 EO patients were stratified by BMI (
ISSN:0269-2813
1365-2036
DOI:10.1111/apt.12270